{"classes":[{"categories":[{"measurements":[{"comment":"The upper limit of the CI for CNS DOR could not be estimated at time of the data cutoff for participants in the alectinib arm.","groupId":"OG000","lowerLimit":"14.8","upperLimit":"NA","value":"17.3"},{"groupId":"OG001","lowerLimit":"2.1","upperLimit":"17.3","value":"5.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"description":"CNS DOR was defined as the time from when response (CR or PR) was first documented to first documented disease progression or death, whichever occurred first. DOR was evaluated for participants who had a best overall response (BOR) of CR or PR.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"OG000","title":"Alectinib"},{"description":"Participants received crizotinib at 250 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"OG001","title":"Crizotinib"}],"paramType":"MEDIAN","populationDescription":"ITT population included all participants randomized in the study, irrespective of whether or not they received study drug. Number analyzed indicates number of participants with a BOR of CR or PR.","reportingStatus":"POSTED","timeFrame":"First occurrence of CNS objective response to first documented disease progression or death, whichever occurs first (assessed every 8 weeks up to 33 months)","title":"CNS DOR IRC-assessed According to RECIST v1.1 Criteria","type":"SECONDARY","unitOfMeasure":"months"}